Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CVS Health Corporation (NYSE: CVS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission (SEC). These filings document material events, financial results, capital markets transactions, governance changes and legal developments that affect CVS Health and its shareholders.
Among the key documents are current reports on Form 8-K, which CVS Health uses to announce items such as quarterly and year-to-date financial results, updated financial guidance, and Investor Day presentations. For example, the company has filed Form 8-K reports furnishing press releases that discuss strategic priorities, revenue and earnings guidance, and non-GAAP measures like adjusted operating income and adjusted earnings per share, along with reconciliations to GAAP metrics.
Other Form 8-K filings describe governance actions, including the Board of Directors’ appointment of J. David Joyner, President and Chief Executive Officer, to the additional role of Chair of the Board. Capital markets activity is also reflected in filings that detail the issuance of senior notes under an Underwriting Agreement, including principal amounts, maturities, interest rates and references to the governing senior indenture and registration statement.
Filings further address legal and subsidiary matters, such as the disclosure that Omnicare, LLC, a wholly owned indirect subsidiary of CVS Health, and certain of its subsidiary entities voluntarily initiated chapter 11 proceedings under the U.S. Bankruptcy Code to address litigation-related monetary damages and other financial challenges. These documents outline the use of debtor-in-possession financing and the evaluation of restructuring options.
On Stock Titan, AI-powered tools summarize and highlight the contents of CVS Health’s SEC filings, helping readers quickly identify key points in lengthy documents such as 8-Ks, and providing context around financial measures, governance changes and risk-related disclosures.
CVS HEALTH Corp executive Heidi B. Capozzi reported routine equity compensation and related tax withholding. She received stock options for 64,670 shares of common stock at $71.82 per share, exercisable in three equal annual installments starting March 31, 2027 and expiring on March 31, 2036. She was also granted 10,025 restricted stock units at $71.82 per share under the 2017 Incentive Compensation Plan, with restrictions lapsing in three equal installments beginning March 31, 2027. In a separate transaction, 1,334 common shares at $72.49 were surrendered to cover withholding taxes on RSU vesting, leaving her with 13,023 directly held common shares.
CVS Health Corp — The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A describing an internal realignment and reporting 0 shares and 0% beneficial ownership of CVS common stock. The filing notes the realignment took place January 12, 2026 and the amendment is signed on 03/26/2026.
Gallina John E reported acquisition or exercise transactions in this Form 4 filing.
CVS Health Corp director John E. Gallina reported receiving a grant of common stock as part of his board compensation. He was awarded 582 shares of CVS common stock on March 19, 2026 at a reference price of $71.86 per share, issued as payment of a pro rata semi-annual retainer under the 2017 Incentive Compensation Plan. Following this grant, he directly owns 582 CVS shares, reflecting a compensation-related equity award rather than an open-market purchase.
CVS Health Corp filed an initial ownership report for John E. Gallina, who is identified as a director of the company. This Form 3 does not list any stock transactions or holdings details in the provided data, serving mainly to register him as an insider for future reporting.
CVS Health Corporation announced that its Board of Directors elected John E. Gallina to the Board, effective March 19, 2026. Gallina is the former Executive Vice President and Chief Financial Officer of Elevance Health, Inc., where he spent nearly 30 years in senior finance and risk roles.
The Board determined that Gallina is an independent director under New York Stock Exchange rules and the company’s Corporate Governance Guidelines. He was also appointed to CVS Health’s Audit Committee and designated an “audit committee financial expert” under SEC rules.
Gallina currently serves on the Board of Arrive AI Inc., where he chairs the audit committee, and holds board roles at two privately held non-profit organizations. His compensation as a non-employee CVS Health director will align with that of other non-employee directors, prorated based on his start date.
CVS Health EVP, CPO and General Counsel Samrat S. Khichi reported a tax-related share disposition. On the vesting of a restricted stock unit award, 7,886 shares of common stock were surrendered at $79.60 per share to cover withholding taxes. After this transaction, he directly owns 29,775 shares of common stock and holds 25,608 shares of restricted stock.
CVS Health Corp director and President & CEO J. David Joyner reported a routine tax-withholding transaction. On February 28, 2026, he surrendered 1,944 shares of common stock at $79.90 per share to cover taxes due on a vested restricted stock unit award. After this, he directly held 49,996 common shares and 74,534 RSU-based common stock equivalents.
CVS Health Corp filed a Form 13F reporting its institutional holdings. The report lists 9 holdings with a combined market value of $135,316,653. The filing was signed by Michael Motolo, Executive Director in Woonsocket, RI on 02-13-2026.
CVS Health Corporation filed its annual report describing a large, diversified health solutions company built around insurance, pharmacy services and retail care delivery in the U.S.
As of December 31, 2025, CVS operated about 9,000 retail locations, more than 800 MinuteClinics and roughly 1,000 walk‑in and primary care clinics, and filled or managed up to 1.9 billion prescriptions through its Health Services segment and 1.8 billion prescriptions through Pharmacy & Consumer Wellness.
The company reports four segments: Health Care Benefits (Aetna-branded medical, Medicare, Medicaid and related products), Health Services (PBM, specialty, value‑based care and in‑home evaluations), Pharmacy & Consumer Wellness (retail pharmacy and front store), and Corporate/Other. CVS highlights heavy use of technology and AI, quality accreditations, extensive provider networks, value‑based primary care, and a Healthy 2030 impact strategy focused on people, business, community and planet.
CVS Health reported strong 2025 top-line growth but sharply lower GAAP profit due to large one-time charges. Total revenues rose 7.8% to a record $402.1 billion, with fourth-quarter revenue up 8.2% to $105.7 billion.
Full-year GAAP diluted EPS fell to $1.39 from $3.66, mainly driven by a $5.7 billion goodwill impairment in the Health Services segment and about $1.2 billion of legacy litigation charges. By contrast, adjusted EPS increased to $6.75 from $5.42, reflecting stronger underlying operations, especially in Pharmacy & Consumer Wellness. Cash flow from operations was $10.6 billion. For 2026, CVS reaffirmed GAAP EPS guidance of $5.94–$6.14 and adjusted EPS of $7.00–$7.20, but lowered its operating cash flow outlook to at least $9.0 billion from at least $10.0 billion.